David C Ward

This inventor holds 25 USPTO granted patents, plus 1 CIPO patent and 2 EPO patents, primarily in Cancer Biomarkers. Top assignees: Yale University, Research, Incorporated, Molecular Staging Inc.. Active years: 1976-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: David C Ward. Retrieved from https://idiyas.com/inventor/david-c-ward

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25

% Patents Active = 96.0

CIPO Patents = 1

EPO Patents = 2 (Patent Applications = 1)

Average Co-Inventor Count = 3.2

ph-index = 15

Forward Citations = 1,787(Granted Patents)

Location History:

Guilford, CT (US) (1976 - 2001)
Madison, CT (US) (1998 - 2005)
Las Vegas, NV (US) (2010 - 2019)

Company Filing History:

Research, Incorporated

patents

1 out of 17

Molecular Staging Inc.

patents

4. 1 out of 834,453

Other

patents

Years Active: 1976-2019

Loading Chart...

Areas of Expertise:

Cancer Protein Biomarkers

Proteomic Techniques

Stem Cell Isolation

Nucleic Acid Detection

Signal Amplification

Fluorescence Hybridization

Rad51 Compositions

Karyotyping

Modified Nucleotides

Diagnostic Medicine

Visualization Polymers

Viral Compounds

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10168334 - Identification of cancer protein biomarkers using proteomic techniques (2019-01-01),

2. 9470688 - Identification of cancer protein biomarkers using proteomic techniques (2016-10-18),

3. 8975379 - Identification of cancer protein biomarkers using proteomic techniques (2015-03-10),

4. 8609414 - Isolation and growth of stem cells from hemangiomas (2013-12-17),

5. 7666583 - Identification of cancer protein biomarkers using proteomic techniques (2010-02-23),

6. 6861222 - Nucleic acid detection using structured probes (2005-03-01),

7. 6686157 - Signal amplification with lollipop probes (2004-02-03),

8. 6548259 - Multiparametric fluorescence in situ hybridization (2003-04-15),

9. 6506563 - Multiparametric fluorescence in situ hybridization (2003-01-14),

10. 6391564 - Methods and compositions utilizing Rad51 (2002-05-21),

11. 6203977 - Delineation of individual human chromosomes in metaphase and interphase cells by in situ suppression hybridization (2001-03-20),

12. 6090539 - Methods and compositions utilizing Rad51 (2000-07-18),

13. 6060251 - Amplification karyotyping (2000-05-09),

14. 6007994 - Multiparametric fluorescence in situ hybridization (1999-12-28),

15. 5869237 - Amplification karyotyping (1999-02-09),

Title: **David C. Ward: Innovator in Cancer Biomarkers**

Introduction

David C. Ward, residing in Madison, CT, is a distinguished innovator recognized for his substantial contributions to the field of cancer research and biomarker identification. With a remarkable total of 25 patents to his name, his work significantly impacts the diagnosis and monitoring of cancer, enhancing the medical community's ability to discriminate between cancerous and healthy subjects.

Latest Patents

Among his latest patents, David C. Ward's significant contributions include groundbreaking methods for the identification of cancer protein biomarkers using proteomic techniques. These innovative methods help diagnose or aid in the diagnosis of cancer by identifying biomarkers exceptionally effective in differentiating between cancer patients and healthy individuals. The unique and novel screening methods employed in this research have led to the identification of specific biomarkers, such as leptin, prolactin, OPN, and IGF-II, which play key roles in diagnosing, prognosing, and monitoring ovarian cancer.

Career Highlights

David C. Ward has collaborated with several organizations during his career, notably Yale University and Research Incorporated. His extensive expertise has propelled advancements in cancer biomarker research, cementing his status as a leading inventor in the scientific community.

Collaborations

Throughout his career, David has worked closely with esteemed colleagues, including Patricia Bray-Ward and Pennina R. Langer. Their collective efforts have fostered innovative approaches to cancer research, further contributing to the body of knowledge in the field.

Conclusion

David C. Ward's innovative spirit and dedication to cancer research underscore his importance in the scientific community. His patents not only reflect his ingenuity but also offer valuable tools for the early diagnosis and monitoring of cancer, ultimately improving patient outcomes and advancing medical science.

Profile summary based on public USPTO records.